Edition:
United Kingdom

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

1.81USD
14 Nov 2018
Change (% chg)

$-0.18 (-9.05%)
Prev Close
$1.99
Open
$1.96
Day's High
$1.98
Day's Low
$1.80
Volume
90,884
Avg. Vol
39,550
52-wk High
$4.04
52-wk Low
$1.80

Latest Key Developments (Source: Significant Developments)

Sophiris Bio Updates On Phase 2B Localized Prostate Cancer Trial
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Sophiris Bio Inc ::SOPHIRIS BIO UPDATES ON PHASE 2B LOCALIZED PROSTATE CANCER TRIAL.SOPHIRIS BIO INC - PREVIOUSLY REPORTED PATIENT DEATH DETERMINED UNLIKELY TO BE RELATED TO TOPSALYSIN.SOPHIRIS - AFTER REVIEW OF AUTOPSY REPORT INVESTIGATOR & CO BELIEVE CAUSE OF DEATH CONSISTENT WITH AUTOPSY FINDING OF SCD PROBABLY DUE TO ARRHYTHMIA.SOPHIRIS BIO INC - AUTOPSY FOUND THAT PATIENT HAD MULTIPLE RISK FACTORS FOR SCD.SOPHIRIS BIO INC - INVESTIGATOR & CO CONCUR PATIENT DEATH EVENT UNLIKELY RELATED TO TOPSALYSIN OR PROCEDURE.SOPHIRIS - CONTINUE TO PLAN & MOVE FORWARD WITH POTENTIAL PHASE 3 STUDY DESIGN BASED ON RESPONSE RATES & SAFETY PROFILE OBSERVED TO DATE.SOPHIRIS - CONCLUSION OF ONGOING INVESTIGATION INTO PREVIOUSLY REPORTED DEATH OF PATIENT IN PHASE 2B TRIAL FOR TREATMENT OF LOCALIZED PROSTATE CANCER.SOPHIRIS BIO INC - REGULATORY AUTHORITIES IN U.S. AND U.K. WHERE STUDY BEING CONDUCTED NOTIFIED.  Full Article

Sophiris Bio Reports Q1 Loss Per Share $0.11
Monday, 14 May 2018 

May 14 (Reuters) - Sophiris Bio Inc ::SOPHIRIS BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS.Q1 LOSS PER SHARE $0.11.SOPHIRIS BIO - EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS TO MIDDLE OF 2019, ASSUMING NO NEW CLINICAL TRIALS ARE INITIATED.AT MARCH 31, 2018, CO HAD CASH, CASH EQUIVALENTS AND SECURITIES AVAILABLE-FOR-SALE OF $22.1 MILLION AND WORKING CAPITAL OF $19.2 MILLION.  Full Article

Sophiris Bio posts Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports third quarter financial results and key corporate highlights.Q3 loss per share $0.09.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Sophiris Bio Inc - qtrly ‍total operating expenses $3.3 million versus $3.7 million.  Full Article

Sophiris Bio Q2 earnings per share $0.02
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports second quarter financial results and key corporate highlights.Q2 earnings per share $0.02.Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Sophiris Bio- not planning on second Phase 3 trial in BPH, unless can secure development partner to fund new clinical trial or obtain other financing​.Sophiris Bio Inc- ‍expects that its cash and cash equivalents will be sufficient to fund its operations through end of 2018​.Sophiris Bio Inc- ‍expects to receive 24- week biopsy data for all patients from first dose of topsalysin in Q1 of 2018​.  Full Article